Calder Biosciences Inc.: Funding, Investors & Team (Sep 2026)

Calder is a clinical-manufacturing stage biotechnology company producing next-generation vaccines that elicit best-in-class responses by using our 3D-Vaxlock™ technology to amplify the strength and breadth of protection. Viruses have evolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock™ technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system and allow billions of people to lead healthy lives.

Calder Biosciences Inc. has raised $1.4M across 2 rounds on record. The most recent is a Seed of $530k announced in Sep 2023.

Calder Biosciences Inc.'s most recent funding round on record is a Seed of $530k, announced in Sep 2023.

Christopher Marshall is listed as CEO at Calder Biosciences Inc..

Calder Biosciences Inc. is based in New York, United States.

Calder Biosciences Inc. is in the 1-10 employee band.

Calder Biosciences Inc.'s latest round of $530k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.